One employee is dismissed, another has resigned, and three others are put on administrative leave.
GlaxoSmithKline (GSK) issued a statement to say it and the scientific publication Nature Medicine recently became aware of allegations of misrepresentation of data in a research paper written by scientists at GSK’s China research center and published in Nature Medicine in 2010 (1). The published study was from preclinical, early-stage research and did not directly involve patients, according to GSK. The article examined the role of interleukin-7 in T helper type 17 cell survival and expansion in treating autoimmune disease.
“The integrity of our research is critical to our work and when these allegations came to light, we immediately contacted the journal to tell them that we were taking the charges seriously and would be investigating thoroughly,” said GSK in the statement. “Regretfully, our investigation has established that certain data in the paper were indeed misrepresented. We’ve shared our conclusion that the paper should be retracted and are in the process of asking all of the authors to sign a statement to that effect, according to Nature Medicine’s procedure.”
GSK says that one individual has been dismissed from GSK, a second has submitted his resignation, and three others have been placed on administrative leave, pending a final review. “We are committed to the highest ethical and scientific standards and regulators, physicians, and patients can have confidence in the research we carry out.” said GSK in its statement.
Reference
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.